Literature DB >> 14596666

Transgenic mice over-expressing galanin exhibit pituitary adenomas and increased secretion of galanin, prolactin and growth hormone.

P Perumal1, M E Vrontakis.   

Abstract

Galanin is a biologically active 29 amino acid peptide, widely distributed in the central and peripheral nervous system, and most abundantly in the hypothalamus where it may serve in the regulation of anterior pituitary hormones. We herein report that mice carrying the rat preprogalanin cDNA specifically targeted to the somatomammotroph cell lineage, under the control of the rat GH promoter, over-express and over-secrete galanin. Galanin peptide is localised within the GH and prolactin secretory granules. GH and prolactin release is increased as well, predominantly in males, while older transgenic animals develop pituitary hyperplasia and adenoma. In both male and female transgenic mice there is a significant increase in serum galanin (P<0.00003 and P<0.001 respectively) and prolactin (P<0.002 and P<0.05 respectively) levels, while only in male transgenic mice is there a significant increase in the serum levels of GH. Furthermore, in male transgenic mice serum prolactin levels are significantly correlated with the serum galanin levels (P<0.03). We conclude that galanin plays a key role in the process of pituitary hyperplasia, acting as a growth factor to promote pituitary cell proliferation, and participates in pituitary adenoma formation not necessarily dependent on oestrogens. Targeted over-expression and over-secretion of galanin in the somatomammotroph cell lineage stimulates predominantly hyperprolactinaemia in an oestrogen-independent manner.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14596666     DOI: 10.1677/joe.0.1790145

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  8 in total

1.  Rap1 mediates galanin receptor 2-induced proliferation and survival in squamous cell carcinoma.

Authors:  Rajat Banerjee; Bradley S Henson; Nickole Russo; Alex Tsodikov; Nisha J D'Silva
Journal:  Cell Signal       Date:  2011-02-21       Impact factor: 4.315

Review 2.  Galanin and its receptors in neurological disorders.

Authors:  Linda Lundström; Anna Elmquist; Tamas Bartfai; Ulo Langel
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

3.  Genomic characterization of human and rat prolactinomas.

Authors:  Yunguang Tong; Yun Zheng; Jin Zhou; Nelson M Oyesiku; H Phillip Koeffler; Shlomo Melmed
Journal:  Endocrinology       Date:  2012-05-25       Impact factor: 4.736

4.  Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.

Authors:  Cameron S Metcalf; Misty D Smith; Brian D Klein; Daniel R McDougle; Liuyin Zhang; Grzegorz Bulaj
Journal:  Neurochem Res       Date:  2017-04-06       Impact factor: 3.996

5.  Increased intake of ethanol and dietary fat in galanin overexpressing mice.

Authors:  Olga Karatayev; Jessica Baylan; Sarah F Leibowitz
Journal:  Alcohol       Date:  2009-12       Impact factor: 2.405

6.  Galanin transgenic mice with elevated circulating galanin levels alleviate demyelination in a cuprizone-induced MS mouse model.

Authors:  Lin Zhang; Wu Yu; Ingo Schroedter; Jiming Kong; Maria Vrontakis
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

Review 7.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

8.  Galanin modulates the neural niche to favour perineural invasion in head and neck cancer.

Authors:  Christina Springstead Scanlon; Rajat Banerjee; Ronald C Inglehart; Min Liu; Nickole Russo; Amirtha Hariharan; Elizabeth A van Tubergen; Sara L Corson; Irfan A Asangani; Charlotte M Mistretta; Arul M Chinnaiyan; Nisha J D'Silva
Journal:  Nat Commun       Date:  2015-04-28       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.